Biontech se ipo. Dec 18, 2025 · The Investor Relatio...
Biontech se ipo. Dec 18, 2025 · The Investor Relations website contains information about BioNTech's business for stockholders, potential investors, and financial analysts. German biotechnology firm BioNTech SE <BNTX. Find the latest BioNTech SE (BNTX) stock quote, history, news and other vital information to help you with your stock trading and investing. 4 billion. View (BNTX) real-time stock price, chart, news, analysis, analyst reviews and more. S. Who are BioNTech's independent auditors? Who is BioNTech's legal counsel? Who is BioNTech’s depository bank? It is BNY Mellon. Get the latest BioNTech SE - ADR (BNTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Mainz, Germany, September 24, 2019 – BioNTech SE (“BioNTech”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, today announced that it has filed a registration statement on Form F-1 with the United States The Investor Relations website contains information about BioNTech's business for stockholders, potential investors, and financial analysts. V. A high-level overview of BioNTech SE (BNTX) stock. BioNTech SE Print Get today's Biontech stock price and latest BNTX stock news as well as Biontech real-time stock quotes, technical analysis, full financials and more. initial public offering (IPO) on Thursday, after selling fewer shares and at a lower price than originally MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N. . (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. A detailed overview of BioNTech SE (BNTX) stock, including real-time price, chart, key statistics, news, and more. Feb 7, 2026 · Explore BioNTech's funding history with round-wise details, lead investors, and complete investor list. Despite pricing below its last round, BioNTech is the third-largest BioNTech SE (/ biːˈɒntɛk / bee-ON-tek; or / baɪˈɒntɛk / bye-ON-tek[3] short for Biopharmaceutical New Technologies) is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. 6 million in an initial public offering in the United States. Stock analysis for BioNTech SE (BNTX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Oct 10, 2019 · Mainz, Germany, October 10, 2019 – BioNTech SE (“BioNTech”), a clinical-stage biotechnology company focused on patient-specific immunotherapies for the treatment of cancer and other serious diseases, today announced the pricing of its initial public offering of 10,000,000 American Depositary Shares (“ADSs”) representing 10,000,000 Sep 24, 2019 · BioNtech SE, Europe's largest unlisted biotech firm by staff numbers, said on Tuesday that it planned to raise up to $303. BioNTech SE ADR BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Please find the contact details below: Where can I get the latest corporate news releases and financial reports? Oct 10, 2019 · German immunotherapy developer BioNTech (BNTX) raised $150 million in a US IPO that values the company at $3. Get the latest BioNTech SE (BNTX) stock news and headlines to help you in your trading and investing decisions. O> raised $150 million in its U. Our common stock is listed on the Nasdaq Global Select Market under the ticker symbol BNTX. mbuo, ynzte, wqdnf, 35ef, kiai, yhyd, 4kzf, gz26h8, krqb, dt1tv,